Autotaxin-IN-7

Autotaxin-IN-7 (45), a pyridine-2-carboxylic derivative, demonstrates subnanomolar ATX inhibition (IC50 = 0.086 nM), with a favorable heart safety profile (hERG > 30 μM) and minimal fibroblast toxicity. Autotaxin-IN-7 (45) suppresses the TGF-β/Smad signaling pathway, downregulating α-smooth muscle actin (α-SMA) and extracellular matrix components (ECM) . Autotaxin-IN-7 (45) is used in the research for pulmonary fibrosis[1].

Product Specifications

UNSPSC

12352005

Target

Phosphodiesterase (PDE) ; TGF-β Receptor

Related Pathways

Metabolic Enzyme/Protease; TGF-beta/Smad

Field of Research

Inflammation/Immunology

Smiles

O=C1N(C2=C(C3=C1N(C=C3C(NC4=CC=CC(C(O)=O)=N4)=O)C5=CN(N=C5)CCC)C=CC=C2)CC

Molecular Formula

C26H24N6O4

Molecular Weight

484.51

References & Citations

[1]Deyi Ma, et al. Development of Tricyclic 4,5-Dihydro-3 H-pyrrolo[2,3- c]quinolin-4-ones as Potent Autotaxin Inhibitors for Pulmonary Fibrosis Treatment In Vivo. J Med Chem. 2025 Apr 10;68 (7) :7476-7498.